Good promotion of the Morgan's valuation of 42c, the untapped potential of our market, and how prepared we are going forward.
Hoping to have ODD Europe granted by end of year!
Back of the envelope calculation from MT - 60,000 US patients, $100k per treatment. Getting only 10-15% of those 60k equates to $600-$900m/annum!
That alone values PAA at $1.23 to $1.85. No P/E ratio, only 10-15% of US market, not taking Europe into account, and nothing else.
Pharmaust - Media & News, page-114
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.5¢ |
Change
0.005(2.78%) |
Mkt cap ! $89.95M | |||
| Open | High | Low | Value | Volume |
| 19.0¢ | 19.0¢ | 18.0¢ | $101.7K | 548.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 200973 | 18.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 136673 | 5 |
View Market Depth
| Last trade - 14.45pm 27/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |